“Safer supply is the thing that changes everything”: the role of prescribed safer supply in rebuilding trust following experiences of medical abandonment Authors: Gillian Kolla, Bernie Pauly, Nancy Henderson, Fred Cameron, Kim Toombs, Emily Clayton, Josh Irvine, Corey Ranger, Lisbet Rygnestad, Andrea Sereda, Karen Urbanoski Published: 2026 ABSTRACT BackgroundPrescribed safer supply provides people dependent on street-acquired opioids with pharmaceutical opioids to reduce overdose risk. Previous experience with the healthcare system - including opioid agonist treatment or high-dose opioids prescribed for pain - is common among people dependent on unregulated opioids, as are experiences of significant stigma when seeking care. Our objective was to examine previous healthcare experiences and how these differ from receiving care in safer supply programs.MethodsUsing reflexive thematic methods, qualitative interviews and focus groups were conducted in 2022 with 38 clients and 10 staff members from two prescribed safer supply programs in different parts of Canada: in London, Ontario and Victoria, British Columbia. Thematic analysis was used to examine themes related to experiences with the healthcare system both prior to initiating safer supply, and following engagement in care in a safer supply program.ResultsPrior to safer supply, participants described three trajectories of medical abandonment: abrupt deprescribing of high-dose opioids despite significant medical complexity, punitive and inadequate opioid agonist treatment, and pervasive stigma in healthcare settings. These experiences left participants deeply mistrustful of healthcare providers and forced to source opioids from the unregulated drug supply. Safer supply programs facilitated re-engagement in care through environments of trust and respect, with provision of opioids as a crucial step toward addressing complex health conditions and achieving social stabilization.DiscussionSafer supply programs meet a critical need for comprehensive substance use care, reducing overdose risk while supporting management of complex medical conditions and social stabilization. For people previously deprescribed from opioid medications, prescribed safer supply assists in repairing trust and facilitating broader healthcare engagement. Our results caution against punitive, surveillance-oriented practices within safer supply prescribing, as these risk replicating the medical abandonment that created the need for alternative care models in the first place. Introduction The North American overdose crisis has led to a rapid increase in opioid-overdose related deaths, primarily from unregulated fentanyl, fentanyl analogues and benzodiazepines permeating the unregulated drug supply. In 2016 (the first year national monitoring data is available) there were 2,831 opioid-toxicity deaths across Canada, representing a rate of 7.8 deaths per 100,000; by 2023 (the year with the highest number of recorded deaths), there were 8,399 opioid-toxicity deaths, representing a national rate of 21.5 deaths per 100,000 [1]. However, there is significant regional variation; in 2023, the western province of British Columbia (BC) had 2608 deaths, representing a rate of 47.1 opioid-toxicty deaths per 100,000, while Ontario, Canada’s most populous province, had 2648 deaths (16.9 per 100,000) [1]. While a suite of interventions have been proposed to address this public health crisis, one of the newer responses is safer supply prescribing, a harm reduction intervention that aims to reduce the risk of unregulated drug toxicity deaths by providing a pharmaceutical prescription of opioid medications of known potency and consistency to people who are dependent on unregulated drugs. A small number of safer supply programs have been piloted since 2020 across Canada, primarily in Ontario and BC. Additionally, in 2020, BC introduced their first provincial safer supply policy known as Risk Mitigation Guidance in response to the dual public health crises of COVID-19 and the drug toxicity crisis, followed by the Prescribed Safer Supply policy guidance in 2021. Due to resource constraints, these programs primarily targeted people at highest risk of overdose who had not experienced sufficient benefit from previous attempts at traditional treatment options like opioid agonist therapy (OAT) [2–7]. Research on prescribed safer supply programs has shown positive outcomes for clients, with quasi-experimental studies showing decreased overdose risk and significant reductions in overdose and all-cause mortality among people receiving safer supply, as well as improvements in clinical outcomes, including reductions in emergency department visits, hospital admissions, admissions for infectious complications, and health care costs [8–10]. Qualitative research and surveys of program participants have also reported reduced use of fentanyl and reductions in frequency of injection among people receiving safer supply; improvements to financial and housing stability; improvements in self-reported health status, and increased stability and agency over drug use patterns [2, 5, 6, 11–21]. One striking finding from the growing body of research on safer supply is the medical and social complexity of people being prescribed safer supply, including high rates of HIV and hepatitis C diagnoses, previous hospitalizations for infectious complications, and previous experiences of OAT [8, 10, 22]. Despite this significant medical complexity, qualitative results document that many safer supply clients express not having their medical or treatment needs met prior to enrolling in safer supply programs, with these programs playing an important role in connecting people to a broad range of health and social services [2, 6, 15, 21, 23]. This suggests that safer supply prescribing may have a role to play as an alternate road to stability for many people whose needs have not been met by existing treatment modalities [10, 24]. Concerns about the over-prescribing of pharmaceutical opioids have dominated discussions on the origins of the current overdose crisis, with comparatively little attention paid to the impacts of opioid deprescribing measures which were put in place as a response [25]. Deprescribing – where people receiving high-dose opioid prescriptions are cut off from prescribed opioid medications – has contributed significantly to overdose mortality over the past ten years [26–29]. Underemphasized within the current literature on the overdose crisis is the way in which deprescribing and losing access to high dose opioid prescriptions - for either pain management or as OAT - leads to an increased risk of both drug use from the unregulated market and associated overdose mortality. This is despite a growing body of research that has documented how rapid opioid tapers and opioid deprescribing measures have resulted in a high risk of negative health outcomes, including increases in mental health crises and suicide, as well as overdose death [30–35]. Concurrently, there has been a small amount of research examining the experiences of people who were deprescribed from high dose opioids prescribed for chronic pain, with qualitative research documenting stigmatizing treatment and high levels of surveillance (i.e. urine drug screening, pill counts), feeling ‘orphaned’, unheard, or having concerns and pain minimized by physicians during tapers, and experiencing high levels of pain and suicidal thoughts during tapering or rapid deprescribing [36, 37]. Existing research on prescribed safer supply highlights two seemingly contradictory findings: that people receiving safer supply were frequently prescribed OAT and pain medications prior to beginning in SSP, yet would describe that their healthcare needs were also not being met [16, 18, 24]. In an attempt to clarify this, the objective of this study is to explore trajectories of care prior to initiating safer supply, including experiences being prescribed and subsequently deprescribed from opioids before starting safer supply, prior experiences receiving OAT, and lack of appropriate care in healthcare setting. Then, we examine the experiences of clients after beginning to receive care from a safer supply program for insights that may be useful in helping to provide comprehensive healthcare to people who use drugs and maintaining their engagement in care. Site descriptions In this study, we use data from a study of two safer supply programs in medium-sized urban settings in different parts of Canada (London, Ontario and Victoria, BC). Recruitment in London occurred in partnership with the London Intercommunity Health Center (LIHC) Safer Opioid Supply (SOS) program, which has been previously described in research and program evaluation [2, 6, 8, 15, 17, 38]. Started in 2016 and using a primary care-based model for providing prescribed safer supply to individuals at high risk of overdose from the toxic drug supply, in 2020 the program received federal pilot funding from Health Canada’s Substance Use and Addiction program that allowed it to expand to provide comprehensive wrap-around health and social services to participants [2, 8]. As part of an equity focused approach to providing care to people experiencing multiple forms of marginalization, at the time of this research, this SOS program cared primarily for clients engaged in survival sex work and/or experiencing homelessness and precarious housing [15, 17]. Clients received individualized prescriptions for SOS medications as one element of the comprehensive primary health care, social care and harm reduction services available to them in a low-barrier, community health centre setting [2]. Clients generally received prescriptions for opioid agonist treatment (primarily methadone or slow-release oral morphine) alongside take-home doses of hydromorphone tablets to replace their use of opioids from unregulated sources [39]. Recruitment in Victoria, BC occurred in partnership with the Victoria SAFER Initiative (SAFER), a community-based prescribed safer supply (PSS) program operated by AVI Health and Community Services that provides pharmaceutical alternatives to the unregulated drug supply alongside integrated health and social supports for people at high risk of overdose. SAFER launched in early 2020 during COVID-19 pandemic onset, alongside federal funding for pilot PSS programs [3], and the release of provincial clinical guidance supporting risk mitigation prescribing in British Columbia [40, 41]. SAFER began as an outreach program where a nurse and harm reduction worker visited encampments and COVID-19 sheltering sites to connect people with prescribers and deliver medications [41]. Early implementation drew on provincial guidance but evolved rapidly in response to participant needs, emerging program data, and community-based research with people who use drugs that identified the need for options better matched to individuals’ opioid tolerance and preferences [5, 41–43]. In collaboration with experienced prescribers and informed by these findings, SAFER staff developed prescribing protocols for fentanyl patches, fentanyl tablets (buccal fentanyl), and injectable sufentanil; in 2021, a dedicated clinical site was established for program participants, enabling the provision of supervised dosing and on-site clinical and social supports [44]. At the time of this research, medications could be prescribed as observed doses at the pharmacy (for opioid agonist treatment) or SAFER clinic (for fentanyl options), or as take-home doses (for oral hydromorphone or oxycodone tablets) to be picked up from a community pharmacy [45]. SAFER is one of only a few PSS programs offering multiple fentanyl formulations [44]. Methods We used a community-based research approach in a study of two safer supply programs in different parts of Canada (London, Ontario and Victoria, BC). People who use drugs – including people receiving safer supply – helped to guide the research process as members of research advisory groups. For this study, two research advisory groups (one in each location) advised on study conception and design, data collection, analysis, and reporting of results. Interview and focus group guides were developed with the research advisory teams, who provided input on question phrasing, flow and additional topic areas. The research advisories also pilot tested the interview and focus group guides. Core members of the research team (including GK, BP, KU) are academic researchers trained in public health and nursing, with substantial experience conducting qualitative research with people who use drugs and who access harm reduction interventions. Academic team members (GK, BP, KU) conducted semi-structured qualitative interviews and focus groups with 38 safer supply clients across both sites in May and June 2022 (n = 18 in Victoria, n = 20 in London), with GK engaging in significant periods on site in both programs conducting research and program evaluations over a period of several years [2, 5, 15, 17, 44]. In total, 2 focus groups occurred in Victoria (n = 9), and 2 focus groups in London (n = 11), with 9 people at each location participating in one-on-one interviews (see Table 1 for more details on client participants). Participants were given a choice of whether to participate in interviews or focus groups to maximize comfort and remove barriers to participation. People with lived experience of substance use assisted with moderation of the focus groups alongside academic researchers, after having completed training in research data collection. Interviews were approximately 45–60 min long and paid $25 honoraria; focus groups were maximum 120 min and paid $50 honoraria. All clients were active participants in the safer supply program at the time of data collection. All clients were recruited and participated in person. Staff invited people to participate and if interested, participants were introduced to the interviewer in a separate room for confidentiality. Additionally, 10 staff members from the two safer supply programs were interviewed from November 2022 to February 2023, using a combination of in-person and virtual one-on-one interviews according to the preference of the interviewee (see Table 2 for more details on staff participants). Interviews with staff were approximately 60–90 min long, and either scheduled during work hours or paid a $50 honoraria. A variety of staff members were interviewed at both sites, including clinical care (i.e. RNs, NPs and MDs) and social care providers, as well as those in management roles. To be eligible to participate, clients and staff members had to be at least 19 years old, able to conduct an interview in English, able to provide informed consent, and be either a current client of or a staff member at one of the two safer supply programs. In the findings, the term ‘staff’ is used to refer to all staff regardless of role to protect their confidentiality. All participants provided informed consent. Study activities were approved by the Research Ethics Board at the University of Victoria (#22–0125). Table 1Sociodemographic Characteristics of Safer Supply Client ParticipantsVictoria, BC (n = 18)London, ON (n = 20)Total (n = 38)Method of participationn (%)n (%)n (%) One-on-one interview9 (50%)9 (45%)18 (47%) Focus group9 (50%)11 (55%)20 (53%)Gender identity n (%) n (%) n (%) Woman, transgender, or non-binary6 (33%)11 (55%)17 (45%) Man12 (67%)9 (45%)21 (55%)Race / ethnicity n (%) n (%) n (%) White9 (50%)15 (75%)24 (63%) Indigenous3 (17%)5 (25%)8 (21%) More than one racial identity2 (11%)02 (5%) Did not respond4 (22%)04 (11%)Age (years) Mean (SD)43.5 (11.4)46.3 (10.6)45.0 (10.9) Range24–6225–6324–63Accommodation type n (%) n (%) n (%) Rented or stable housing4 (22%)9 (45%)13 (34%) No fixed address3 (17%)6 (30%)9 (24%) Shelter, SRO, or treatment centre8 (44%)5 (25%)13 (34%) Did not respond3 (17%)03 (8%)Indigenous includes First Nations, Métis, and Inuit. Two participants in Victoria identified with more than one racial identity and also identified as Indigenous, and are counted in the 'More than one racial identity' rowNotes: SRO Single Room Occupancy hotel Table 1Sociodemographic Characteristics of Safer Supply Client ParticipantsVictoria, BC (n = 18)London, ON (n = 20)Total (n = 38)Method of participationn (%)n (%)n (%) One-on-one interview9 (50%)9 (45%)18 (47%) Focus group9 (50%)11 (55%)20 (53%)Gender identity n (%) n (%) n (%) Woman, transgender, or non-binary6 (33%)11 (55%)17 (45%) Man12 (67%)9 (45%)21 (55%)Race / ethnicity n (%) n (%) n (%) White9 (50%)15 (75%)24 (63%) Indigenous3 (17%)5 (25%)8 (21%) More than one racial identity2 (11%)02 (5%) Did not respond4 (22%)04 (11%)Age (years) Mean (SD)43.5 (11.4)46.3 (10.6)45.0 (10.9) Range24–6225–6324–63Accommodation type n (%) n (%) n (%) Rented or stable housing4 (22%)9 (45%)13 (34%) No fixed address3 (17%)6 (30%)9 (24%) Shelter, SRO, or treatment centre8 (44%)5 (25%)13 (34%) Did not respond3 (17%)03 (8%)Indigenous includes First Nations, Métis, and Inuit. Two participants in Victoria identified with more than one racial identity and also identified as Indigenous, and are counted in the 'More than one racial identity' rowNotes: SRO Single Room Occupancy hotel Sociodemographic Characteristics of Safer Supply Client Participants Indigenous includes First Nations, Métis, and Inuit. Two participants in Victoria identified with more than one racial identity and also identified as Indigenous, and are counted in the 'More than one racial identity' row Notes: SRO Single Room Occupancy hotel Table 2Sociodemographic Characteristics of Safer Supply Staff ParticipantsVictoria, BC (n = 5)London, ON (n = 5)Total (n = 10)Gender identityn (%)n (%)n (%) Woman, transgender, or non-binary4 (80%)5 (100%)9 (90%) Man1 (20%)0 (0%)1 (10%)Race / ethnicity n (%) n (%) n (%) White5 (100%)5 (100%)10 (100%)Age (years) Mean (SD)37.4 (5.2)35.6 (6.3)36.5 (5.5) Range32–4529–4229–45Role, n (%) Clinical staff (MD, NP, RN)2 (40%)3 (60%)5 (50%) Management1 (20%)1 (20%)2 (20%) Social support staff2 (40%)1 (20%)3 (30%)Time in current role (years) Mean (SD)2.0 (0.8)4.2 (2.1)3.0 (1.8) Range1.0–3.02.0–6.01.0–6.0 Table 2Sociodemographic Characteristics of Safer Supply Staff ParticipantsVictoria, BC (n = 5)London, ON (n = 5)Total (n = 10)Gender identityn (%)n (%)n (%) Woman, transgender, or non-binary4 (80%)5 (100%)9 (90%) Man1 (20%)0 (0%)1 (10%)Race / ethnicity n (%) n (%) n (%) White5 (100%)5 (100%)10 (100%)Age (years) Mean (SD)37.4 (5.2)35.6 (6.3)36.5 (5.5) Range32–4529–4229–45Role, n (%) Clinical staff (MD, NP, RN)2 (40%)3 (60%)5 (50%) Management1 (20%)1 (20%)2 (20%) Social support staff2 (40%)1 (20%)3 (30%)Time in current role (years) Mean (SD)2.0 (0.8)4.2 (2.1)3.0 (1.8) Range1.0–3.02.0–6.01.0–6.0 Sociodemographic Characteristics of Safer Supply Staff Participants Interview and focus group guides addressed multiple elements of safer supply program operations and experiences receiving care from safer supply programs. Interviews were recorded using Zoom or a handheld audio recorder (when data collection was done in person) and transcribed verbatim by a confidential professional transcriber. Academic team members reviewed transcripts for accuracy before importing into Nvivo (Version 12) to facilitate coding, and GK led this analysis. Informed by the work of Braun and Clarke and their six phase framework for thematic analysis, we used reflexive thematic analysis in this study. Data were open coded by several academic research team members (GK, KF, NH, MG) who consulted regularly to review coded transcripts and emerging codes. Coding was a flexible, iterative process with a focus on researcher reflexivity as coding proceeded. Preliminary themes were shared with advisory team members for further feedback. As part of this inductive initial analysis, initial codes were developed and used to develop a coding framework that could be used by multiple members of the research team with coding proceeding iteratively [46, 47]. The coding framework was used as a flexible scaffold to organise and interrogate codes, which facilitated an iterative process among research team members to developing early themes around experiences receiving healthcare services and OAT prior to receiving safer supply, and the differences in client descriptions of receiving care in safer supply programs. Our inductive analysis does not aim for data saturation, and was used to refine major areas of analytic interest to the two major themes that are explored in detail below [47, 48]. The first centres on experiences of medical abandonment prior to receiving safer supply, while the second explores safer supply prescribing and program participation being experienced as a form of re-engagement in care. Results Our results centre on two major themes identified in interviews and focus groups with clients and staff. The first section explores the experience of medical abandonment among participants. We identify three trajectories of medical abandonment: (1) Frequent past experiences of rapid opioid tapers or complete and precipitous deprescribing of opioid medications; (2) Frequent attempts at opioid agonist treatment (OAT) that did not meet their needs or OAT being used in punitive way, and: (3) Experiences of rampant stigma and discrimination in healthcare settings (including the denial of pain medications in hospital). In the second section, we explore how clients and staff describe safer supply programs as a new trajectory of care for opioid use disorder (especially among people with multiple previous attempts at traditional OAT) and as a way to repair previous experiences of medical abandonment, which allows for re-engagement in healthcare and social services. Medical abandonment Past experience of rapid tapers and/or deprescribing of opioid medications When asked about their experiences being prescribed opioids (including as OAT and/or for pain management) prior to beginning safer supply, many participants recounted significant medical complexity and multiple co-morbidities, including past major traumas, injuries and/or chronic pain that had necessitated high-dose, long term opioid prescriptions to manage symptoms. Despite major medical complexity, many participants described stability in their lives while receiving high-dose, long term opioids in the past, which ceased when healthcare providers decided to stop prescribing opioids to them: When I first started using, I hurt my back terribly and was on two milligrams of Dilaudid, three times a day. And I’d renew it every month. Over two years I got up to four Dilaudid four times a day, and renewing every three weeks. And my doctor freaked out and is like: “You’re turning into a junkie, we’re cutting you off.” And so, I was immediately trying to buy pills on the street because I could barely walk. I was really, really messed up. It’s been ten years and I still have a bad limp. And if I could’ve been prescribed medicine through that whole period, it wouldn’t be an issue. I probably would have finished my degree. I could be working. (Client interview) When I first started using, I hurt my back terribly and was on two milligrams of Dilaudid, three times a day. And I’d renew it every month. Over two years I got up to four Dilaudid four times a day, and renewing every three weeks. And my doctor freaked out and is like: “You’re turning into a junkie, we’re cutting you off.” And so, I was immediately trying to buy pills on the street because I could barely walk. I was really, really messed up. It’s been ten years and I still have a bad limp. And if I could’ve been prescribed medicine through that whole period, it wouldn’t be an issue. I probably would have finished my degree. I could be working. (Client interview) As highlighted above, participants would frequently describe opioid tolerance and increases in dosages over time, followed by an abrupt discontinuation of all prescribed opioids due to a change in framing from their prescriber. This change in framing from ‘valid chronic pain issue’ to ‘addiction’ led doctors to abruptly cease prescribing opioids, leaving participants in a position of having to turn to the unregulated drug supply to avoid pain and withdrawal. Some clients described a total lack of understanding of the ways in which opioids caused dependency, and their surprise at experiencing withdrawal when cut off:“I had surgery on my wrist and I got hooked on pain pills. Right? They gave me morphine, oxys and percs for a year and a half. And he [physician] cut me off cold turkey. And I didn’t know what sickness was cause I didn’t know anything about pills. I had a job, I worked, and lost it all. Right? Because they felt that I was addicted to the pills. I definitely was, but I didn’t know what sickness was until that next day when I didn’t have any pills. And I didn’t understand what was wrong.” (Client interview). “I had surgery on my wrist and I got hooked on pain pills. Right? They gave me morphine, oxys and percs for a year and a half. And he [physician] cut me off cold turkey. And I didn’t know what sickness was cause I didn’t know anything about pills. I had a job, I worked, and lost it all. Right? Because they felt that I was addicted to the pills. I definitely was, but I didn’t know what sickness was until that next day when I didn’t have any pills. And I didn’t understand what was wrong.” (Client interview). In both of the quotes above, participants described stability while receiving a high dose opioid prescription that allowed them to work and maintain their job, or engage in schooling. This stability ended when they lost access to high-dose opioids, and experienced sudden and terrible withdrawal due to opioid dependency. Similar to previous research documenting how rapid tapers and abrupt cessation of opioid therapy can lead to increased risk of overdose mortality and that inappropriate tapering among chronic pain patients can lead to loss of functional abilities [33, 35], experiences of complete and immediate cessation of high-dose opioid prescriptions - without even receiving tapering - were common past experiences among people currently receiving safer supply. As highlighted above, these decisions did not centre their wellbeing or a recognition that dependency is a predictable result of long-term opioid treatment. The rapid cessation of opioids led to drastic impacts on their quality of life, as with the participant above who was unable to continue university due to unmanaged pain and the participant who could not continue to work due to withdrawal. Participants also described how these rapid discontinuations lacked any ongoing care planning, leaving clients in pain, effectively abandoned by their healthcare provider, and without options for continuing to have their pain control needs met safely within a medical context due to difficulties in finding a new prescriber after having been labelled with an “addiction”. Previous experiences of OAT that did not meet their needs Another group of participants described substantial past experience receiving OAT, with several attempts at multiple forms of treatment over a period of years: As far as I was concerned I deserved to be on there [safer supply program]. Like, I’m not twenty five years old; I’m sixty. I’ve done your programs. I’ve done your recovery programs. I’ve done your treatment programs. I’ve done your methadone. I’ve done your Suboxone. I think that it’s fair to say that I had put forth all the efforts. Plus I got maturity. They’ve made it affordable. They’ve made it possible to come off the dope. (Client interview) As far as I was concerned I deserved to be on there [safer supply program]. Like, I’m not twenty five years old; I’m sixty. I’ve done your programs. I’ve done your recovery programs. I’ve done your treatment programs. I’ve done your methadone. I’ve done your Suboxone. I think that it’s fair to say that I had put forth all the efforts. Plus I got maturity. They’ve made it affordable. They’ve made it possible to come off the dope. (Client interview) Participants frequently explained that they had tried multiple forms of OAT that did not meet their needs prior to receiving safer supply, with OAT frequently described as being used in punitive ways and/or withheld as punishment for using other drugs that were also experienced as medical abandonment. For example this participant with severe chronic pain described being abruptly deprescribed from methadone after testing positive for cocaine: I’m supposed to have pills. I had a [methadone] script but I lost it because I tested positive for cocaine…But I’m supposed to be on pain killers the rest of my life. I’ve had four back surgeries. And I almost lost my leg in a car accident, so I have a lot of pain. Chronic pain. (Client interview) I’m supposed to have pills. I had a [methadone] script but I lost it because I tested positive for cocaine…But I’m supposed to be on pain killers the rest of my life. I’ve had four back surgeries. And I almost lost my leg in a car accident, so I have a lot of pain. Chronic pain. (Client interview) Here, use of cocaine while receiving OAT resulted in the immediate loss of this participant’s methadone prescription, highlighting not only the punitive rules around OAT, but the ways in which care can be cut off and patients abandoned if they do not meet the strict expectations of OAT programs. Staff also reflected on how offering OAT to clients asking for safer supply after having already tried OAT felt insulting. It suggested to clients that their experience was not being believed, or that their healthcare provider was not taking them seriously when they explained that something wasn’t working for them. As one staff member explained:I don’t offer alternatives [OAT] anymore cause I find it insulting. Like if people are asking for this, I’m not gonna say: “But there’s a methadone clinic down the street.” If I came in and said, “My arm is broken” and somebody said: “Great, there’s a massage therapist down the street,” that would be incredibly insulting. People are specifically asking for safer supply. People have been on methadone. And I find too, in terms of harm reduction, methadone is like a wolf in sheep’s clothing. Like it’s saying it’s harm reduction, but it’s not. Well, the way it’s utilized here, it’s not. People are withheld methadone for using other substances. There’s a huge stigma. A lot of the times it’s in clinics that are not harm reduction focused. It works for a very specific population, and that’s great. But if harm reduction is ice cream, it’s very bad frozen yogurt. (Staff interview) I don’t offer alternatives [OAT] anymore cause I find it insulting. Like if people are asking for this, I’m not gonna say: “But there’s a methadone clinic down the street.” If I came in and said, “My arm is broken” and somebody said: “Great, there’s a massage therapist down the street,” that would be incredibly insulting. People are specifically asking for safer supply. People have been on methadone. And I find too, in terms of harm reduction, methadone is like a wolf in sheep’s clothing. Like it’s saying it’s harm reduction, but it’s not. Well, the way it’s utilized here, it’s not. People are withheld methadone for using other substances. There’s a huge stigma. A lot of the times it’s in clinics that are not harm reduction focused. It works for a very specific population, and that’s great. But if harm reduction is ice cream, it’s very bad frozen yogurt. (Staff interview) Across both client and staff interviews, it was frequently identified that participants had received OAT - often multiple times over multiple years - and found it inadequate to meet their needs, or experienced abrupt discontinuation of OAT medications due to not following OAT clinic rules, such as rules stating that recreational use of other substances while on OAT is not allowed. This service provider also highlights how people are often seeking safer supply because OAT has not worked for them in the past or was delivered in ways that were not harm reduction focused, highlighting the programmatic differences in the delivery of safer supply vs. OAT. Experiences of stigma and discrimination in healthcare settings A third form of medical abandonment is the stigma and discrimination that participants described healthcare settings. In addition to being deprescribed from opioid medications including OAT, many participants also described how opioids were withheld or under-dosed in medical settings, such as when they had to access care in the emergency department or hospital:Oh, I fucking hate the hospital. They make you wait forever. They don’t do anything. They usually just wait for you to leave. Well, with me. Cause they know I’ll leave eventually. That’s a big thing, is the stigma. Like, the hospital not prescribing opiates. You know? They had this thing where they see it as like, it’s like the devil. (Client interview) Oh, I fucking hate the hospital. They make you wait forever. They don’t do anything. They usually just wait for you to leave. Well, with me. Cause they know I’ll leave eventually. That’s a big thing, is the stigma. Like, the hospital not prescribing opiates. You know? They had this thing where they see it as like, it’s like the devil. (Client interview) Participants highlighted how stigma played a role in this negative treatment, which included the perception that opioid medications and other treatments were withheld so that people who use drugs would leave prior to receiving medical care. Similarly, another participant experiencing a severe medical condition described how they were given a dose of opioids significantly lower than the prescription they received on a daily basis, provoking them to leave prior to completing treatment:Some doctors won’t even look at you. They’re like: “Who gives a fuck?”, you know? Like I do not go to [name of local hospital]. I do not go there. Because I went there the one time, and that’s the reason why I almost died from the meningitis. Because they were giving me a Dilaudid 2 every six hours. And I was prescribed fucking six of them every two hours. And that’s my prescription. Like, I’d been on these pills and they wouldn’t give me my hydromorphone. And I’m like: “You know what? You guys can fucking shove your medica-…” And I started pulling everything out of me. And they’re like: “Well you’re gonna die.” I said: “Well, I don’t give a fuck, man. I’m leaving. Cause you guys are giving me a Dilaudid 2. Like, this is why I’m freaking out.” And they’re like: “No, you’re gonna…” Well I just left anyways. And then it was a counsellor here that brought me to [hospital] and I didn’t even know. I didn’t even know I came here. That’s how sick I was. Like my legs finally stopped working and everything. (Client focus group) Some doctors won’t even look at you. They’re like: “Who gives a fuck?”, you know? Like I do not go to [name of local hospital]. I do not go there. Because I went there the one time, and that’s the reason why I almost died from the meningitis. Because they were giving me a Dilaudid 2 every six hours. And I was prescribed fucking six of them every two hours. And that’s my prescription. Like, I’d been on these pills and they wouldn’t give me my hydromorphone. And I’m like: “You know what? You guys can fucking shove your medica-…” And I started pulling everything out of me. And they’re like: “Well you’re gonna die.” I said: “Well, I don’t give a fuck, man. I’m leaving. Cause you guys are giving me a Dilaudid 2. Like, this is why I’m freaking out.” And they’re like: “No, you’re gonna…” Well I just left anyways. And then it was a counsellor here that brought me to [hospital] and I didn’t even know. I didn’t even know I came here. That’s how sick I was. Like my legs finally stopped working and everything. (Client focus group) In both cases, lack of adequate treatment of pain and/or withdrawal led to participants leaving prior to completing medical treatment despite having serious health concerns. The regularity of this type of negative experience was corroborated by safer supply program staff, who explained how they were frequently told of extremely negative experiences by their clients. Some doubted that the reality could be as bad as described, only to have the stories confirmed when reading the hospital notes or discharge summaries, as this staff member at a safer supply program describes: I think when you first start you’re like: “Oh, this has to be just somebody’s perception. This can’t be what actually happened.” And then you read hospital notes and you’re like, “There’s no perception there. It was just a terrible experience.” There are things that we see – either being completely ignored, or dismissed, or things completely missed, to people being incredibly stigmatized. (Staff interview) I think when you first start you’re like: “Oh, this has to be just somebody’s perception. This can’t be what actually happened.” And then you read hospital notes and you’re like, “There’s no perception there. It was just a terrible experience.” There are things that we see – either being completely ignored, or dismissed, or things completely missed, to people being incredibly stigmatized. (Staff interview) As described above, staff members in safer supply programs were sometimes shocked by the negative treatment their clients received when attempting to access healthcare, even in situations where this could lead to severe health outcomes, or even death. A staff member also reflected on how participants internalized this stigma from their interactions with the healthcare system: Here’s this thing that you’ve been told for as long as you can remember: “It’s dirty and you’re dirty for doing it. And you’re dirty for letting it do this to you.” All of this stuff, until that’s just the way you’re defined. And a lot of people will start to define themselves that way. And, you know, you can’t even walk into an emergency department and get help for being legitimately sick without being reminded that you’re dirty: “We don’t like you”. (Staff interview) Here’s this thing that you’ve been told for as long as you can remember: “It’s dirty and you’re dirty for doing it. And you’re dirty for letting it do this to you.” All of this stuff, until that’s just the way you’re defined. And a lot of people will start to define themselves that way. And, you know, you can’t even walk into an emergency department and get help for being legitimately sick without being reminded that you’re dirty: “We don’t like you”. (Staff interview) Further, anticipation of this negative treatment contributed to participants’ avoidance of healthcare services, even when medical care was desperately needed. Staff recognized the profound negative impacts of experiencing multiple forms of deprescribing, negative and stigmatizing treatment within the healthcare system on the clients they were working with in safer supply programs, describing it as a form of medical abandonment. As one staff member described as they struggled to hold back tears: The idea of being abandoned or betrayed by an institution [medicine] that we’ve always been told is the backbone of our social support system. The thing that is there even if no one else is. And, where you go in your time of crisis and your time of urgent need. That has always been built up in our society as the place that will never fail you, and it won’t even love you. Won’t even help you. Won’t even support you. And I think that is a profound betrayal. And that makes it very, very hard for people to trust anyone and to believe professionals. And I think that it just adds to one’s self-perception, right? Of who they are, and it’s really, really problematic. (Staff interview) The idea of being abandoned or betrayed by an institution [medicine] that we’ve always been told is the backbone of our social support system. The thing that is there even if no one else is. And, where you go in your time of crisis and your time of urgent need. That has always been built up in our society as the place that will never fail you, and it won’t even love you. Won’t even help you. Won’t even support you. And I think that is a profound betrayal. And that makes it very, very hard for people to trust anyone and to believe professionals. And I think that it just adds to one’s self-perception, right? Of who they are, and it’s really, really problematic. (Staff interview) This medical abandonment – experienced and described in multiple ways by clients and staff – was not only a betrayal that left participants deeply mistrustful of medical institutions and professionals, but also entrenched a feeling of being unworthy of care in the people who repeatedly experienced it. Safer supply as re-engagement in care Access to a new trajectory of care for people experiencing complex health needs due to substance use The main focus of prescribed safer supply programs was to provide access to a regulated pharmaceutical to people at high risk of overdose. However, many programs were forced by necessity to become an integrated site for the provision of complex multidisciplinary care as clients presented with so many unmet health and social needs:The aim of these programs is to get people safer drugs so that they’re not at risk of overdose. But what we’ve actually built is a program for complex care for folks who’ve fallen through every gap in the system. And these programs have become this triage mechanism for folks who have failed methadone, have failed Suboxone, nothing’s working. They’re living in an encampment. There’s nothing out there for them. And so the program’s actually stepped in to meet the needs of this group of people. Which is important and crucial, as these folks were not having any needs met. (Staff interview) The aim of these programs is to get people safer drugs so that they’re not at risk of overdose. But what we’ve actually built is a program for complex care for folks who’ve fallen through every gap in the system. And these programs have become this triage mechanism for folks who have failed methadone, have failed Suboxone, nothing’s working. They’re living in an encampment. There’s nothing out there for them. And so the program’s actually stepped in to meet the needs of this group of people. Which is important and crucial, as these folks were not having any needs met. (Staff interview) Staff noted that often, their clients had tried every other option within the conventional addiction treatment and hospital systems, and consistently been failed by them. They expressed that safer supply programs were achieving success in re-engaging people in care who would otherwise be falling through the cracks of the healthcare system:I never had a doctor period. I had so many health issues it was crazy. It [safer supply] just…it saved my life in every aspect. (Client interview) I never had a doctor period. I had so many health issues it was crazy. It [safer supply] just…it saved my life in every aspect. (Client interview) Prescribed safer supply allowed many clients to engage in care in a different way as it provided a new treatment option when they had previously tried all other options. Staff were cognisant of the impact these previous negative experiences had on clients, describing their attempts to use safer supply programs as spaces to create new narratives and positive associations with healthcare:There’s some clients that just have never really had that with anyone within the health care sector especially. Because it’s historically been such a stigmatizing and negative place for them. So we really try to break down all of those barriers and all of those stereotypes of walking into a health care setting and flip that. (Staff interview) There’s some clients that just have never really had that with anyone within the health care sector especially. Because it’s historically been such a stigmatizing and negative place for them. So we really try to break down all of those barriers and all of those stereotypes of walking into a health care setting and flip that. (Staff interview) Throughout our interviews, participants highlighted how safer supply re-engages those who have experienced medical abandonment by providing a new medication option to offer and support people to move away from the unregulated drug market. In doing so, participants highlight the critical importance of countering previous experiences of stigma and discrimination which have contributed to trajectories of medical abandonment in healthcare. By meeting their need for a regulated source of opioids, safer supply programs were able to foreground participant autonomy, their preferences for healthcare, and the goals that mattered to clients. Rebuilding trust for individuals who had been forced into the unregulated market by deprescribing For clients navigating chronic pain, their past experience often involved years of trying to find medical providers willing to care for them or provide pain relief. Several described finally receiving pain management due to begin admitted to a safer supply program: They’ve got me where I need to be. Like, I’m not sick. I’m not doped up, I’m not in pain. I can walk. (Client interview). Many struggled to understand why they had been denied an adequate prescription to meet their pain management needs for so long: I’m not using nearly as much as I had to use before. Like, hardly at all. When before I had to. I mean Kadian wasn’t really doing anything for my pain. So, I have some pain management now…and I don’t know why nobody would prescribe it to me until I got to come here. (Client interview) I’m not using nearly as much as I had to use before. Like, hardly at all. When before I had to. I mean Kadian wasn’t really doing anything for my pain. So, I have some pain management now…and I don’t know why nobody would prescribe it to me until I got to come here. (Client interview) By accessing safer supply programs, clients expressed having their needs met – often for the first time ever, or in many years. In this way, access to regulated opioids functioned as an enabling condition for self-determination - allowing participants to direct their attention and energy toward their own priorities, whether related to housing, relationships, work, or other areas of their lives. Safer supply as ‘the thing that changes everything’ Staff described how providing access to a regulated drug supply was a crucial tool to repairing the medical abandonment clients have faced in the past, due to the repeated experiences patients had of being deprescribed, denied adequate opioid medications for pain, and stigma and discrimination. In addition to the medications, the different approach to provision of care within safer supply programs - taking clients seriously, listening to them, and believing their experience of pain - were seen as a powerful ways of centring client autonomy, and showing clients that they are worthy of trust, respect, and care.I think that safer supply is the thing that changes everything. Not just because of the opioids, right? Obviously the opioids play a really big role. But beyond that, it’s a such a different kind and a different level of support to receive from others: “There is this inherent trust that this team is placing in me that no one has ever done before. There is this faith in me that I have never received before. Like, I come in, I tell her what I’m using - which I’m never able to tell anybody - and she believes me. And then gives me drugs to keep me safe”. Like - it’s a big deal! For people who have not had anything even remotely close to that ever. And, and as a matter of fact receive the exact opposite every time they attempt to engage with a professional or an organization. It’s not understanding, it’s judgment. It’s, you know, assumptions. It’s the belief that you’re inherently flawed, or dirty, or dangerous. And instead, here’s these crazy people who have just decided to do this thing that most people have never heard of. It’s so life changing. It’s everything changing. (Staff interview) I think that safer supply is the thing that changes everything. Not just because of the opioids, right? Obviously the opioids play a really big role. But beyond that, it’s a such a different kind and a different level of support to receive from others: “There is this inherent trust that this team is placing in me that no one has ever done before. There is this faith in me that I have never received before. Like, I come in, I tell her what I’m using - which I’m never able to tell anybody - and she believes me. And then gives me drugs to keep me safe”. Like - it’s a big deal! For people who have not had anything even remotely close to that ever. And, and as a matter of fact receive the exact opposite every time they attempt to engage with a professional or an organization. It’s not understanding, it’s judgment. It’s, you know, assumptions. It’s the belief that you’re inherently flawed, or dirty, or dangerous. And instead, here’s these crazy people who have just decided to do this thing that most people have never heard of. It’s so life changing. It’s everything changing. (Staff interview) The prescribing - in many cases re-prescribing - of high dose opioids that occurs in safer supply programs is not only a means by which staff are helping to build connections with clients, but also to address the stigma, negative treatment and medical abandonment clients had been subjected to because of their use of high-dose opioids. Staff noted that once participants realized they were finally being listened to and their needs were being met through a safer supply program, this created space for them to begin addressing other goals and priorities in their lives, including healthcare needs: It takes a few weeks to months before they trust that they have their prescription. They have their daily budget of opioids. But once they’ve settled into that we actually see them coming to see the doctor, which was almost never before. And then the second thing that we see is a decrease in their involvement in crime and sex work. So that’s often what they’ll report: “Since we started I haven’t been arrested. I haven’t been to jail in a year. I’m doing a lot less sex work. I can stay at home now”. And then the third positive outcome is as we gain more time, the chronic health improvements, like getting peoples’ HIV under control. Getting their hep C treated. Starting to use chronic mental health medications. And social stabilization, I’m finding is coming even later. Like, people want to connect with family, but that takes even more time. So, lots of benefits but definitely pretty standardly spaced in terms of what presents first. (Staff interview) It takes a few weeks to months before they trust that they have their prescription. They have their daily budget of opioids. But once they’ve settled into that we actually see them coming to see the doctor, which was almost never before. And then the second thing that we see is a decrease in their involvement in crime and sex work. So that’s often what they’ll report: “Since we started I haven’t been arrested. I haven’t been to jail in a year. I’m doing a lot less sex work. I can stay at home now”. And then the third positive outcome is as we gain more time, the chronic health improvements, like getting peoples’ HIV under control. Getting their hep C treated. Starting to use chronic mental health medications. And social stabilization, I’m finding is coming even later. Like, people want to connect with family, but that takes even more time. So, lots of benefits but definitely pretty standardly spaced in terms of what presents first. (Staff interview) The physical and social stability brought about from having access to a stable source of pharmaceutical medications allowed for clients to begin to attend to both physical and mental health needs. This stability and relief was also described by participants:I can wake up in the morning and I think about what I want to eat instead of: “Where am I gonna get high. What am I gonna do to get my next fix?”. Instead, I wake up when I feel like having an egg sandwich, you know? Like, breakfast. And it feels good to have that feeling again. (Client focus group) I can wake up in the morning and I think about what I want to eat instead of: “Where am I gonna get high. What am I gonna do to get my next fix?”. Instead, I wake up when I feel like having an egg sandwich, you know? Like, breakfast. And it feels good to have that feeling again. (Client focus group) Knowing they had access to a stable, pharmaceutical prescription and would not have to worry about withdrawal decreased stress for participants, and allowed them to attend to other needs. Program staff explained that for participants who had been struggling to survive day-to-day, having their high dose opioid needs met opened the door for their other healthcare needs to be addressed:We had somebody who said that they had wanted to die for twenty years, so they never attended to their healthcare. And now they want to live, so they gave me a list of all the things that they’ve been ignoring for twenty years. We see a lot of that. We see a lot of: “I’ve been just living day to day. Now that I’m not doing that… So like, I’ve had chest pain for like two years. What do you think?” A lot of that. (Staff interview) We had somebody who said that they had wanted to die for twenty years, so they never attended to their healthcare. And now they want to live, so they gave me a list of all the things that they’ve been ignoring for twenty years. We see a lot of that. We see a lot of: “I’ve been just living day to day. Now that I’m not doing that… So like, I’ve had chest pain for like two years. What do you think?” A lot of that. (Staff interview) A safer supply prescription offered participants the opportunity to begin thinking about their future, rather than only their immediate needs. And because they have prioritized the rebuilding of trust with clients, safer supply program staff were pivotal to helping repair people’s trust in the healthcare system:There’s also that culture of trust. I was used to coming from a psych emerg background. You’re the narc. You are the person that if you say the wrong thing, or the right thing, you’re gonna end up admitted to hospital. Or, on a form [a mental health order to remain in hospital]. Or, police called: “I don’t trust you”. Whereas here, people trust me enough to say, “I don’t like that you did this” or “I would like this”. Or people end up disclosing things. And I can help people because they say, “I trust you. Let me tell you about this problem I’ve been having for a while and I’ve just been too anxious or afraid to say”. So we’re actually able to help, because our clients let us help them. The clients are choosing to participate with us. You could have people come in saying: “I don’t want to talk to you. I don’t want anything else. Give me my D’s [Dilaudids]. I’m gonna go”, and people don’t do that. People could very easily choose to not engage. (Staff interview) There’s also that culture of trust. I was used to coming from a psych emerg background. You’re the narc. You are the person that if you say the wrong thing, or the right thing, you’re gonna end up admitted to hospital. Or, on a form [a mental health order to remain in hospital]. Or, police called: “I don’t trust you”. Whereas here, people trust me enough to say, “I don’t like that you did this” or “I would like this”. Or people end up disclosing things. And I can help people because they say, “I trust you. Let me tell you about this problem I’ve been having for a while and I’ve just been too anxious or afraid to say”. So we’re actually able to help, because our clients let us help them. The clients are choosing to participate with us. You could have people come in saying: “I don’t want to talk to you. I don’t want anything else. Give me my D’s [Dilaudids]. I’m gonna go”, and people don’t do that. People could very easily choose to not engage. (Staff interview) This culture of trust within safer supply programs emerges from the non-punitive approach to working with clients, founded in a willingness to prescribe pharmaceutical opioids as part of a harm reduction approach to healthcare. The provision of pharmaceutical opioids - which is a major and crucial need for clients due to high opioid tolerance because of histories of chronic pain conditions and/or dependence on the street-supply of fentanyl - provides clients with the space to open up about both their opioid- and other health-related needs. It is also a different experience than other interactions within the healthcare system, where drug use is stigmatized or punished by deprescribing or through a refusal to prescribe opioids to treat pain, withdrawal or dependency. In this way, the provision of high-dose opioid prescriptions within safer supply programs and the approach to care provision centred on individualizing care to meet each client’s needs is a first step in repairing previous negative experiences within the healthcare system, and addressing other health and social care needs. Discussion This study explores experiences of medical abandonment prior to receiving safer supply, including abrupt deprescribing from high-dose opioid medications prescribed for pain, inadequate or punitive approaches to OAT, and pervasive stigma in healthcare settings. These experiences were described as a form of medical abandonment, which left participants deeply mistrustful of healthcare providers and institutions. In contrast, safer supply program staff facilitated re-engagement in care by repairing trust, first by meeting participants pharmaceutical opioid needs, while also creating supportive environments characterized by respect and individualized care rather than surveillance. Our results highlight how safer supply programs provide an important dimension of autonomy for clients that merits attention. At their core, these programs operate from the assumption that people who use opioids are capable of managing their medications safely and in ways that address their needs related to withdrawal and pain. Our results suggest that affording participants greater control over the conditions under which they receive medications and broader healthcare can support deeper engagement with care and enable them to reclaim agency over their health and lives. This is particularly important given the literature documenting how increased scrutiny on opioid prescribing and the implementation of policies meant to curb it has led to strained relationships between people receiving opioid prescriptions and healthcare providers, as well as an environment where patients feel disempowered when decisions regarding opioid prescribing are made, or worse, abandoned completely through deprescribing and tapering [49–51]. Importantly, our results also highlight the significant medical complexity that is being cared for within safer supply programs, including signficiant medical co-morbidities, painful medical conditions and previous attempts at OAT [7, 8, 10, 24]. Our findings document that a nuanced understanding of the role of safer supply programs is necessary, as these are not simply programs that provide pharmaceutical alternatives to reduce overdose risk, but are filling a crucial role of providing complex care for people who have “fallen through every gap in the system”. The medical and social complexity of safer supply clients’ situations, including high rates of HIV, hepatitis C, previous hospitalizations for infectious complications, untreated chronic conditions, and multiple “failed” attempts at OAT [8, 10, 22] suggests that this population requires more intensive support than traditional primary care or addiction medicine programs are able to provide [7, 24, 52]. Building on this, our key findings are two-fold. First, similar to existing research [2], our results reinforce that safer supply programs are meeting a need for comprehensive primary and substance use care that provides not only pharmaceutical alternatives to the unregulated drug supply, but also support management of both complex and chronic medical conditions, while also supporting social stabilization. Second, our findings suggest that provision of pharmaceutical opioids, particularly to people previously deprescribed or denied these medications, is not merely a harm reduction intervention but a crucial first step in repairing trust and facilitating the comprehensive healthcare engagement necessary for care of complex health issues. This is particularly important given both the health and social harms (i.e. job loss and inability to remain in school) that participants describe having experienced following deprescribing. The enourmous relief that participants in our study express upon finding a safer supply prescriber who trusts them when it comes to opioid prescribing highlights both the stigma faced by people who use opioids, and the difficulty in finding a healthcare provider who is willing to recognize the expertise that people who use opioids, and individualize care to their situations and needs. This is of particular importance in conversations around opioid prescribing in the current environment of concern about ‘over-prescribing’. Deprescribing and the overdose crisis Our findings extend existing research documenting the harms of rapid opioid tapers and deprescribing [30–33, 35]. In our study, many participants described stability while receiving high-dose opioid prescriptions for chronic pain conditions, including maintaining employment, attending university and managing daily activities. This ended abruptly when high-dose opioid prescriptions were discontinued without tapering, transition planning or provisions for ongoing care. The role that deprescribing plays in increasing overdose risk is often overlooked in discussions of the current overdose crisis, as loss of access to pharmaceutical opioids can drive people to procure opioids from unregulated sources where dose and composition are unknown, significantly increasing overdose risk [26–28, 53]. Increases in opioid overdoses as a result of interventions deployed to reduce population-wide levels of opioid prescribing were amplified by the rapid shift in the unregulated drug supply to fentanyl, fentanyl analogues and other adulterants during this time period - a development modelling had predicted [54]. In Canada, this “pendulum swing” was characterized by a sharp rise in opioid prescribing - leading to a peak in 2011–2016 depending on province - followed by a precipitous drop in opioid prescribing across the country [55–57]. The harms caused by medical abandonment of people on high dose opioids in this period of rapid deprescribing are not frequently acknowledged in the medical or public health literature. Taken alongside evidence that prescribed safer supply can reduce overdose mortality and lead to significant improvements in health outcomes [8–10, 16], there is a need for a nuanced approach to opioid prescribing that acknowledges that for some people, maintenance on high dose opioids in settings such as safer supply programs may produce health benefits and stability. Our findings also highlight the inadequate care that people who use drugs often received from the broader healthcare system. While people who use drugs are often framed as a ‘hard-to-reach’ population, research in Ontario during the COVID-19 pandemic found that 25% of people who died of opioid overdose had interacted with the healthcare system in the week before their death [58], with other research documenting frequent, negative and stigmatizing experiences when accessing the healthcare system among people who use drugs [59–63]. Taken alongside this existing research, our results point to the missed opportunities for care and support when people who use drugs do interact with the healthcare system. There is a strong need to ensure that withdrawal and pain are adequately managed in hospital settings [64, 65], as well as a fundamental transformation in how the healthcare system treats people who use drugs, including addressing the rampant stigma and discrimination that created demand for alternative care models like safer supply programs in the first place. Similar to other research on safer supply, our findings highlight that many safer supply clients had tried OAT multiple times over many years without being retained in treatment [8, 10, 22]. Current Canadian OAT guidelines recommend methadone or buprenorphine products as first-line treatment options, yet retention rates are low and have been falling as unregulated markets transitioned to fentanyl [66–68]. The delivery of OAT in ways that centre surveillance and punitive measures - including deprescribing as punishment for using other substances, excessive surveillance through urine drug screens, and abstinence-focused program rules - can contribute to negative experiences and feelings of medical abandonment [24, 69, 70]. However, safer supply and OAT are not mutually exclusive; emerging research demonstrates that people receiving both OAT and safer supply medications concurrently experience improved retention in care [71–73]. Rather than positioning prescribed safer supply in opposition to OAT, these approaches should be seen as complementary options within a broader continuum of care that provides multiple treatment options in an attempt to meet a diversity of needs. Danger of replicating punitive models A critical concern emerging from our findings are the risk that safer supply programs could adopt the same punitive, surveillance-oriented approaches that have characterized pain management and traditional OAT delivery. The current political climate around safer supply - characterized by push-back from some addiction medicine providers and media reports - creates pressure for safer supply prescribers to demonstrate control over clients through monitoring and increased surveillance using urine drug screens, witnessed dosing, and prescribing only to “deserving” patients [24, 74–76]. Our results suggest that these measures would be deeply counterproductive. Our findings suggest that the success of safer supply programs in re-engaging clients depends fundamentally on building trust by meeting people where they are, believing their reports of pain and levels of use, and avoiding carceral modes of surveillance. If safer supply programs adopt the surveillance and punitive practices that frequently characterize OAT delivery, they risk replicating the very conditions that led to medical abandonment in the first place. A policy change announced by the BC government in 2025 requiring transition to witnessed dosing for all safer supply patients exemplifies this risk [77]. This policy change comes despite robust evidence of positive health impacts and reductions in overdose mortality among people receiving safer supply [8–10, 16, 20], as well as research exploring that while diversion of medication occurs, it is often driven by a need to support community members in withdrawal, experiencing pain, or at high risk of overdose [78–80]. Additionally, ethical analyses of safer supply programs have highlighted the need to balance potential for population level harms from increased prescribing of pharmaceutical opioids and subsequent potential for diversion with the individual-level health benefit and reductions in overdose risk from careful prescribing to individuals [81, 82]. While clinical guidance on managing this transition highlights dangers of a return to the toxic drug supply as a consequence of this policy change, it also outlines a protocol for deprescribing that may bring about the abrupt cessation of prescribing of high dose opioids [83]. This could provoke a return to unregulated opioid use and heightened overdose risk that safer supply was meant to address, and that our findings have highlighted as being detrimental because it destabilizes carefully built relationships of trust and care. Following recent provincial policy changes, the Victoria-based program in our study has shifted program delivery to prioritize observed dosing within clinical or pharmacy settings in accordance with current guidance. While some oral medications (e.g., hydromorphone or oxycodone tablets) may be provided as take-home doses in limited or exceptional circumstances, the overall model centres on witnessed administration. For people who have experienced repeated medical abandonment, the shift from take-home prescriptions to mandatory witnessed dosing may be experienced as yet another abandonment - a return to surveillance and control after finally finding care that treated them with respect and autonomy. Future research will need to examine the impacts of this provincial policy change on participants. Limitations This study has several stengths and limitations. A key strength is the integration of people who use drugs in the research process as full partners, allowing their perspectives to be included and reflected in research design and analysis. Our analysis is focused on two programs in different provinces (Ontario and BC) that both experienced safer supply scale-up, but with differences in support from government and health-system partners at different points in time. While the consistency in themes across both sites lends credibility to the findings, since data were collected in only two urban settings – both with a highly toxic and volatile drug supply – our findings may not extend to other geographical areas or rural/remote areas with different unregulated drug supplies, or to jurisdictions with different program models. Our study also relies on participant recall of previous experiences, though consistency in both staff accounts and in participant experiences across both locations strengthens confidence in the dependability of findings. As all participants in this study were accessing safer supply, the perspectives of those who had accessed the program but stopped their participation, or who were not able to access safer supply at all (with the latter group constituting the overwhelming majority of people who use drugs in both BC and Ontario) are not reflected in the data [7]. Conclusion Our findings highlight how the widespread negative experiences of deprescribing and stigmatizing medical care prior to receiving safer supply could be characterized as a form of medical abandonment. By meeting the need for access to a regulated source of high-dose opioids, safer supply programs were able to begin to repair trust and facilitate re-engagement in healthcare, particularly for those with complex care needs. However, prescribed safer supply has become politicized and the conditions that led to the inadequate care that necessitated safer supply programs not only remain unexamined, they are now being replicated with current policy changes in some regions [83, 84]. The healthcare system’s treatment of people who use drugs - characterized by abrupt deprescribing, punitive OAT delivery, pervasive stigma, and denial of adequate pain management - represents a continuing crisis in the provision of adequate care for people who use drugs that requires urgent attention. The success of safer supply programs in engaging a population experiencing both inadequate medical care and high levels of medical complexity highlights broader healthcare system failures. The principles that allowed safer supply to be a tool to re-engage people in care - trust, respect, patient-centered care, and harm reduction approaches to opioid prescribing - could be usefully applied throughout the healthcare system.